What is the official ID of this bill?

The official print number for this legislation is HR 6101.

When did the legislative process begin?

The process officially started on 2021-12-01.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr6101/BILLS-117hr6101ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Who is the primary sponsor?

The primary sponsor is Rep. Carter, Earl L. "Buddy" [R-GA-1].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 6101

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Increased Transparency in Medicaid Drug Pricing

Q: What are the main provisions?

Key points include: Requires Medicaid drug payments to pharmacies to be the actual drug cost plus a dispensing fee, stopping hidden markups by middlemen. Limits fees paid to middlemen managing drug benefits to a reasonable amount. Makes drug pricing data collected from pharmacies publicly available to increase transparency. Protects pharmacies providing discounted drugs under a federal program (340B).

This bill aims to increase transparency in drug pricing within the Medicaid program. It requires middlemen (like PBMs) to pass the actual drug cost to pharmacies and limits their fees, potentially lowering program costs and ensuring fair payment for pharmacies.

Key points

Requires Medicaid drug payments to pharmacies to be the actual drug cost plus a dispensing fee, stopping hidden markups by middlemen.

Limits fees paid to middlemen managing drug benefits to a reasonable amount.

Makes drug pricing data collected from pharmacies publicly available to increase transparency.

Protects pharmacies providing discounted drugs under a federal program (340B).

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Drug Price Transparency in Medicaid Act of 2021

Print number: HR 6101

Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Process start date: 2021-12-01

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-04-17

Source data: api.congress.gov

AI work logs for this document launch

Increased Transparency in Medicaid Drug Pricing

Key Questions about Increased Transparency in Medicaid Drug Pricing